MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types

The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. The purpose of the Expansion part is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness. This study will enroll patients with triple-negative breast cancer (TNBC), endometrial cancer (EC), non-small cell lung cancer (NSCLC, adenocarcinoma), and ovarian cancer. If it is determined that you meet all of the study entry requirements, you will get an intravenous (IV) infusion of MORAb-202 once every 3 weeks (21 day cycle).

Are you Eligible? (Inclusion Criteria)

• Aged ≥18 years
• Ability to provide a tumor tissue from a previous biopsy or provide a fresh biopsy
• Diagnosis of triple-negative breast cancer (TNBC), endometrial cancer (EC), non- small cell lung cancer (NSCLC, adenocarcinoma), ovarian cancer, primary peritoneal cancer or fallopian tube cancer.
• Adequate kidney, bone marrow, and liver function.